Intratumoral Treatment with Chemotherapy and Immunotherapy for NSCLC with EBUS-TBNA 19G

Conclusions: Intratumoral treatment combination with cisplatin plus immunotherapy indifferent of nivolumab or pembrolizumab combination is an effective choice. In specific for those with endobronchial lesions. Moreover; patients with programmed death-ligand-1 ≥ 50 had their performance status and disease progression improved over the eight month observation.

Source: Journal of Cancer - April 19, 2021 Category: Cancer & Oncology Authors: Paul Zarogoulidis, Wolfgang Hohenforst-Schmidt, Haidong Huang, Jun Zhou, Qin Wang, Xiangqi Wang, Ying Xia, Yinfeng Ding, Chong Bai, Christoforos Kosmidis, Konstantinos Sapalidis, Chrysanthi Sardeli, Kosmas Tsakiridis, Bojan Zaric, Tomi Kovacevic, Vladimir Tags: Research Paper Source Type: research